Shares of Kintara Therapeutics, Inc. (NASDAQ:KTRA – Get Free Report) dropped 6.3% on Monday . The company traded as low as $0.16 and last traded at $0.16. Approximately 628,766 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 10,382,123 shares. The stock had previously closed at $0.17.
Kintara Therapeutics Stock Down 6.3 %
The company has a 50-day moving average of $0.20 and a 200-day moving average of $0.18. The company has a market cap of $9.02 million, a PE ratio of -0.04 and a beta of 0.81.
About Kintara Therapeutics
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients.
Further Reading
- Five stocks we like better than Kintara Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- The Average 401k Balance by Age Explained
- The Risks of Owning Bonds
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
